Published Data in Primary Renal Cell Cancer

RESIRT was the first-in-human trial to assess SIRT for the treatment of primary renal cell carcinoma (RCC) unsuitable for conventional therapy.1

This pilot study of 21 patients demonstrated

  • Partial response (PR) in 1/20 (5%)
  • Stable disease (SD) in 18/20 (90%)
  • Pseudoprogressive disease in 1/20 (5%)
  • Good tolerability at all dose levels
  • No dose-limiting toxicity
  • No serious adverse events (SAEs) or SAEs related to SIR-Spheres® Y-90 resin microspheres

SIRT with SIR-Spheres Y-90 resin microspheres may be a feasible treatment option for RCC patients who are unsuitable for conventional therapy, and further clinical studies are warrantied.

1 Clark, W. et al. Society of Interventional Radiology (SIR) 42nd Annual Scientific Meeting, J Vasc Interv Radiol 2017; 28 (Suppl): S164 Abs. 379.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage